Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Santhera Pharmaceuticals Holding AG's enterprise value is $309.50 Mil.
Santhera Pharmaceuticals Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-39.14 Mil. Therefore, Santhera Pharmaceuticals Holding AG's EV-to-EBITDA for today is -7.91.
SPHDF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.13 Med: -2.42 Max: 57.57
Current: -7.93
During the past 13 years, the highest EV-to-EBITDA of Santhera Pharmaceuticals Holding AG was 57.57. The lowest was -22.13. And the median was -2.42.
SPHDF's EV-to-EBITDA is ranked worse than 100% of 397
companies
in the Biotechnology industry
Industry Median: 12.31
vs SPHDF: -7.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Santhera Pharmaceuticals Holding AG's PE Ratio (TTM) for today is calculated as:
Santhera Pharmaceuticals Holding AG's share price for today is $23.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Santhera Pharmaceuticals Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.667.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG EV-to-EBITDA Chart
SPHDF vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's EV-to-EBITDA falls into.
Santhera Pharmaceuticals Holding AG's current Enterprise Value is $309.50 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Santhera Pharmaceuticals Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-39.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG (SPHDF) has a EV-to-EBITDA of -7.91 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Santhera Pharmaceuticals Holding AG. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #999999 out of 397 companies in the Biotechnology industry.
Is Santhera Pharmaceuticals Holding AG's EV-to-EBITDA too high?
Santhera Pharmaceuticals Holding AG's current EV-to-EBITDA is -7.91. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #999999 out of 397 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #999999 out of 397 companies for EV-to-EBITDA. This places Santhera Pharmaceuticals Holding AG in the lower half of its industry. The industry median EV-to-EBITDA is 12.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.31, based on 397 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Santhera Pharmaceuticals Holding AG. For the Biotechnology industry, the median EV-to-EBITDA is 12.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current EV-to-EBITDA is -7.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Santhera Pharmaceuticals Holding AG (SPHDF) has a current EV-to-EBITDA of -7.91. The stock's GF Value™ is $35.65, compared to a current price of $23.25 — trading 34.8% below its estimated fair value. The current EV-to-EBITDA is -7.91. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (SPHDF), the current EV-to-EBITDA is -7.91 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (SPHDF) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of $23.25 is trading 34.8% below its estimated GF Value™ of $35.65.
Key valuation signals for SPHDF:
EV-to-EBITDA: -7.91
GF Value™: $35.65 vs. price of $23.25 (34.8% below fair value)
No single metric tells the full story. See the SPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG Business Description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score
Get the complete analysis for SPHDF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPHDF has been successfully added to your 
